Abliva AB
Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. The company is developing KL1333 that is in Phase 2 clinical trial to treat chronic fatigue and myopathy in genetically confirmed adult patients with primary mitochondrial disease; and NV354, which has completed preclinical development for the treatment of mitochondrial disease with neurologic … Read more
Abliva AB (ABLI) - Net Assets
Latest net assets as of December 2024: Skr61.69 Million SEK
Based on the latest financial reports, Abliva AB (ABLI) has net assets worth Skr61.69 Million SEK as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr73.55 Million) and total liabilities (Skr11.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr61.69 Million |
| % of Total Assets | 83.87% |
| Annual Growth Rate | 23.05% |
| 5-Year Change | -56.05% |
| 10-Year Change | -60.14% |
| Growth Volatility | 157.31 |
Abliva AB - Net Assets Trend (2007–2024)
This chart illustrates how Abliva AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Abliva AB (2007–2024)
The table below shows the annual net assets of Abliva AB from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr61.69 Million | -12.77% |
| 2023-12-31 | Skr70.72 Million | -56.95% |
| 2022-12-31 | Skr164.29 Million | +295.61% |
| 2021-12-31 | Skr41.53 Million | -70.41% |
| 2020-12-31 | Skr140.36 Million | +9.83% |
| 2019-12-31 | Skr127.80 Million | +31.73% |
| 2018-12-31 | Skr97.01 Million | -8.35% |
| 2017-12-31 | Skr105.85 Million | -37.11% |
| 2016-12-31 | Skr168.30 Million | +8.74% |
| 2015-12-31 | Skr154.78 Million | +43.53% |
| 2014-12-31 | Skr107.84 Million | +44.48% |
| 2013-12-31 | Skr74.64 Million | +18.40% |
| 2012-12-31 | Skr63.04 Million | +95.99% |
| 2011-12-31 | Skr32.17 Million | -21.89% |
| 2010-12-31 | Skr41.18 Million | +305.01% |
| 2009-12-31 | Skr10.17 Million | -13.07% |
| 2008-12-31 | Skr11.70 Million | +544.77% |
| 2007-12-31 | Skr1.81 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Abliva AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 97493185300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr80.59 Million | 130.65% |
| Other Components | Skr958.50 Million | 1553.79% |
| Total Equity | Skr61.69 Million | 100.00% |
Abliva AB Competitors by Market Cap
The table below lists competitors of Abliva AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Playstudios Inc
NASDAQ:MYPS
|
$46.61 Million |
|
Red Robin Gourmet Burgers Inc
NASDAQ:RRGB
|
$46.61 Million |
|
Chain Chon Industrial Co Ltd
TWO:5014
|
$46.63 Million |
|
E&P Financial Group Ltd
AU:EP1
|
$46.64 Million |
|
Ecoplastic Corporation
KQ:038110
|
$46.59 Million |
|
EURO PRATIK SALES LIMITED
NSE:EUROPRATIK
|
$46.56 Million |
|
Thunderbird Entertainment Group Inc
OTCQX:THBRF
|
$46.56 Million |
|
Mayfair Gold Corp
OTCQX:MFGCF
|
$46.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Abliva AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 70,718,000 to 61,688,000, a change of -9,030,000 (-12.8%).
- Net loss of 89,954,000 reduced equity.
- New share issuances of 79,420,000 increased equity.
- Other comprehensive income decreased equity by 802,999.
- Other factors increased equity by 2,306,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-89.95 Million | -145.82% |
| Share Issuances | Skr79.42 Million | +128.74% |
| Other Comprehensive Income | Skr-803.00K | -1.3% |
| Other Changes | Skr2.31 Million | +3.74% |
| Total Change | Skr- | -12.77% |
Book Value vs Market Value Analysis
This analysis compares Abliva AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.60x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 5.20x to 11.60x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | Skr0.09 | Skr0.44 | x |
| 2008-12-31 | Skr0.58 | Skr0.44 | x |
| 2009-12-31 | Skr0.48 | Skr0.44 | x |
| 2010-12-31 | Skr1.94 | Skr0.44 | x |
| 2011-12-31 | Skr1.52 | Skr0.44 | x |
| 2012-12-31 | Skr2.76 | Skr0.44 | x |
| 2013-12-31 | Skr2.95 | Skr0.44 | x |
| 2014-12-31 | Skr2.99 | Skr0.44 | x |
| 2015-12-31 | Skr3.64 | Skr0.44 | x |
| 2016-12-31 | Skr2.92 | Skr0.44 | x |
| 2017-12-31 | Skr1.77 | Skr0.44 | x |
| 2018-12-31 | Skr1.21 | Skr0.44 | x |
| 2019-12-31 | Skr0.73 | Skr0.44 | x |
| 2020-12-31 | Skr0.55 | Skr0.44 | x |
| 2021-12-31 | Skr0.11 | Skr0.44 | x |
| 2022-12-31 | Skr0.22 | Skr0.44 | x |
| 2023-12-31 | Skr0.07 | Skr0.44 | x |
| 2024-12-31 | Skr0.04 | Skr0.44 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Abliva AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -145.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.19x
- Recent ROE (-145.82%) is below the historical average (-67.19%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -67.64% | 0.00% | 0.00x | 1.67x | Skr-1.41 Million |
| 2008 | -13.32% | -171.41% | 0.07x | 1.05x | Skr-2.73 Million |
| 2009 | -15.03% | -34.48% | 0.39x | 1.11x | Skr-2.55 Million |
| 2010 | -11.59% | -138.26% | 0.08x | 1.02x | Skr-8.89 Million |
| 2011 | -29.14% | -168.93% | 0.16x | 1.05x | Skr-12.61 Million |
| 2012 | -23.20% | -1336.30% | 0.02x | 1.12x | Skr-21.28 Million |
| 2013 | -29.59% | -418.58% | 0.06x | 1.18x | Skr-29.88 Million |
| 2014 | -41.18% | -594.92% | 0.05x | 1.27x | Skr-52.88 Million |
| 2015 | -63.86% | -3601.88% | 0.01x | 1.24x | Skr-104.23 Million |
| 2016 | -45.19% | -501714.29% | 0.00x | 1.16x | Skr-85.78 Million |
| 2017 | -66.25% | -247140.74% | 0.00x | 1.19x | Skr-76.80 Million |
| 2018 | -70.49% | -1367460.00% | 0.00x | 1.19x | Skr-78.07 Million |
| 2019 | -60.16% | -57368.66% | 0.00x | 1.16x | Skr-89.65 Million |
| 2020 | -42.66% | -27723.61% | 0.00x | 1.07x | Skr-73.92 Million |
| 2021 | -297.45% | -81786.75% | 0.00x | 1.42x | Skr-127.65 Million |
| 2022 | -51.72% | -274077.42% | 0.00x | 1.12x | Skr-101.39 Million |
| 2023 | -135.06% | -69714.60% | 0.00x | 1.24x | Skr-102.58 Million |
| 2024 | -145.82% | 0.00% | 0.00x | 1.19x | Skr-96.12 Million |
Industry Comparison
This section compares Abliva AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,025,542
- Average return on equity (ROE) among peers: -144.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Abliva AB (ABLI) | Skr61.69 Million | -67.64% | 0.19x | $46.60 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |